1-12 of 12
Nizar Jacques Bahlis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Mirco Friedrich, Niklas Kehl, Simon Steiger, Tim Robin Wagner, Katharina Lindner, Michael Kilian, Julius Michel, Sebastian Uhrig, Raphael Lutz, Nina Prokoph, Alexandra M Poos, Lukas John, Lilli Sophie Sester, Niels Weinhold, Stefan Fröhling, Edward W Green, Lukas Bunse, Paola Neri, Nizar Jacques Bahlis, Karsten Rippe, Stefan Eichmüller, Carsten Müller-Tidow, Hartmut Goldschmidt, Michael Platten, Marc S Raab
Journal: Blood
Blood (2022) 140 (Supplement 1): 604–605.
https://doi.org/10.1182/blood-2022-169721
Published: 2022
Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar Jacques Bahlis, Michael H. Tomasson, Mohamad Mohty, Ruben Niesvizky, Ajay K. Nooka, Salomon Manier, Christopher Maisel, Yogesh Jethava, Joaquin Martinez-Lopez, H Miles Prince, Bertrand Arnulf, Paula Rodriguez Otero, Guenther Koehne, Cyrille Touzeau, Noopur Raje, Shinsuke Iida, Marc-Steffen Raab, Eric Leip, Sharon Sullivan, Umberto Conte, Andrea Viqueira, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 391–393.
https://doi.org/10.1182/blood-2022-162440
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7261–7263.
https://doi.org/10.1182/blood-2022-163809
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Diana Cortes-Selva, Tineke Casneuf, Deeksha Vishwamitra, Sarah Stein, Tatiana Perova, Sheri Skerget, Elena Ramos, Laure van Steenbergen, Dries De Maeyer, Rengasamy Boominathan, Onsay Lau, Cuc Davis, Arnob Banerjee, Tara Stephenson, Clarissa M. Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Usmani, Nizar Jacques Bahlis, Niels WCJ Van De Donk, Raluca Verona
Journal: Blood
Blood (2022) 140 (Supplement 1): 241–243.
https://doi.org/10.1182/blood-2022-162709
Published: 2022
Journal Articles

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Holly Lee, Paola Neri, Sungwoo Ahn, Ranjan Maity, Noemie Leblay, Bachisio Ziccheddu, Monika Chojnacka, Rémi Tilmont, Elie Barakat, Ola Landgren, Francesco Maura, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 252–253.
https://doi.org/10.1182/blood-2022-167602
Published: 2022
Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 388–390.
https://doi.org/10.1182/blood-2022-166494
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Mohamed A Badawi, Benjamin Engelhardt, Jesus Badillo, Ahmed Abbas Suleiman, Leanne Lash Fleming, Yan Luo, Jonathan L. Kaufman, Nizar Jacques Bahlis, Rajeev Menon, Ahmed Hamed Salem
Journal: Blood
Blood (2022) 140 (Supplement 1): 10122–10123.
https://doi.org/10.1182/blood-2022-166429
Published: 2022
Journal Articles

Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma

Paola Neri, Sungwoo Ahn, Holly Lee, Noemie Leblay, Mirco Friedrich, Ranjan Maity, Rémi Tilmont, Elie Barakat, Marc S Raab, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 2093–2094.
https://doi.org/10.1182/blood-2022-164717
Published: 2022